Trial Design
The Redyor study is a prospective randomized single-blind clinical trial aimed to determine the benefits of early rehabilitation to preserve swallow function and quality of life in patients with HNC receiving radiotherapy, following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (31). Throughout the recruitment period, patients who provide their informed consent (Additional file 1) to participate will be randomized to one of two groups: early intervention or post-CRT intervention. No major changes to methods after the start of the study are planned. This trial has been approved by the local Clinical Ethics Committee (Additional File 2).
Settings and locations
Recruitment will be carried out in the Radiotherapy Department at the Parc de Salut Mar (Hospital del Mar and Hospital de l’Esperança), Barcelona, Catalonia, Spain. Baseline dysphagia assessments will be performed in the Swallowing Disorders Unit of the Physical Medicine and Rehabilitation Department at Hospital de l’Esperança and all VFSS assessments will be conducted in collaboration with a radiologist. Statistical analysis will be done at the Hospital del Mar, in the Medical Research Institute (IMIM). Study sites and phases are summarized in the flow diagram (Figure 1).
Eligibility criteria
Patients with advanced HNC receiving radiotherapy will be eligible to participate in this clinical trial. Potential participants will be excluded if they have previous history of HNC and/or head or neck radiation therapy or surgical treatment, or of dysphagia due to causes other than cancer. Inclusion and exclusion criteria are listed in Table 1. During the study period, the patient will be excluded from the study if any of the following occurs: emergence of any of the exclusion criteria, onset of any disease or medical condition that will make it difficult for the patient to continue participation, decision to withdraw from the study for any reason, transfer out of the service area, or death, impossibility to practice exercises due to medical condition.
Intervention
The training protocol consists of IEMT and standard swallowing exercises. Patients will be instructed to maintain a rate of 15–20 breaths/min using the Orygen-Dual® valve (described elsewhere in detail) (21,22), a respiratory device that allows patients to train inspiratory and expiratory muscles simultaneously. Training loads will be set at a pressure equivalent to 10 maximal repetitions (if tolerated). These external pressures will be regulated weekly at 30% of maximal inspiration/expiration respiratory measures obtained. Patients will be instructed to perform 3 sets of 5 repetitions and standard swallowing exercises (mobility and tonicity exercises of the tongue, palate, larynx, and constrictor muscles), 3 times/day, 5 days/week, for 21 weeks. An experienced swallowing therapist will supervise IEMT weekly. The protocol will be the same for both groups, but one group will start 2 weeks before CRT and the other one will begin immediately after completing CRT (Figure 1).
Outcome measures
Main outcome variable:
- Change in dysphagia severity observed by VFSS and assessed with the Penetration-Aspiration Scale: scores 1–2 indicate normal swallowing, 3–5 penetration, and ≥6 aspiration.
Secondary outcome variables:
- Change in quality of life, assessed with the European Organization of Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ-C30) and its Head and Neck Cancer Module (QLQ-H&N35).
- Mouth opening or the maximal interincisor opening (MIO) of the mouth, using the Therabite® range of motion scale
- Maximum isometric tongue pressure in an anterior position
- Maximum inspiratory and expiratory pressures (PImax and PEmax, respectively).
- Impaired security (tone of voice, coughing during or after eating, or desaturation >3% compared to baseline pulse oximetry) and efficacy in oral and pharyngeal phases of swallowing with the use of the Volume-Viscosity Swallow Test.
- Subjective difficulty of swallowing assessed by a Visual Analogic Scale (VAS) ranging from 0 to 10; a low score indicates no difficulties in eating and a high score, no oral intake.
- Peak Cough flow (PCF) will be used to evaluate the effect of IEMT on voluntary cough. It is measured with spirometer in liters/minute. Patients will be instructed to perform 3 repetitions of voluntary cough, the best one will be chosen.
Participant Timeline
Eligible patients will be randomized and referred to the Rehabilitation Department for function assessment and intervention. The study outcomes will be assessed at baseline (2-week pre-CRT, t0), at the beginning of CRT (t1), at the end of CRT (t3), and thereafter at 3 months (t4), 6 months (t5), and 12 months (t6). The Redyor schedule of enrollment is shown in Figure 2.
Sample size calculation
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, a total sample size of 52 patients will be required to detect a difference ≥10 (SD 11) units in the test of quality of life and 2 (SD 2.3) units in the PAS. In order to account for estimated 20% loss to follow-up, 5 patients have been added, resulting 26 patients on each group.
Assignment of interventions
Allocation:When a new patient meets the eligibility criteria, a researcher (PF) in the Radiotherapy Department will inform the researcher responsible for participant randomization (OPC), who will allocate the patient to one of the study groups using a simple random number generator program. The patient will then be referred to the Rehabilitation department and the secretary responsible for scheduling the exercise intervention will be informed of the patient’s exercise timeline.
Blinding:The interdisciplinary researchers (EM, AGS, PF) will be blinded to study group assignments over the entire study period. After data analysis has been completed, results will be released to all patients and to participating clinicians and researchers.
Data collection, management, and analysis
Data collection methods: The main outcomes will be collected by means of a Data Collection Logbook specially designed for this study. This logbook will include the EAT–10 and both quality of life questionnaires (EORTC-QLQ-C30 and QLQ-H&N35). One member of the investigation team (NBS) shall be responsible for the collection and processing of data related to main outcome variables. To promote participant retention, patients will perform a weekly supervised session; any patient not attending these scheduled sessions will be contacted by telephone.
Data management:An individual code will be used to identify each participant in this study. Only one of the two principal investigators (AGS) will have access to the database and shall be responsible for its management.
Statistical methods:Numerical variables will be expressed descriptively as mean and standard deviation (SD).. Student t-test for paired data will be used to compare the quantitative variables before and after the intervention, and Student t-test for independent samples for inter-group comparison of pre- and post-intervention changes. At a later stage, mixed models will be performed to test changes in parameters and the between-group differences in evolution, adjusting by possible confounders. The evaluation of the correlations between variables will be based on the quantitative variables obtained from the various studies and bivariate (ordered Spearman correlation) and multivariate (multiple regression) analysis. Reasons for protocol non-adherence will be registered. The level of alpha risk accepted for all tests will be 0.05.
The evaluation of the correlations between variables will be based on the quantitative variables obtained from the various studies and bivariate (ordered Spearman correlation) and multivariate (multiple regression) analysis. Reasons of protocol non-adherence will be registered and missing data will be discarded. The level of alpha risk accepted for all tests will be 0.05.
Monitoring:Given the non-pharmacological nature of this study, a data monitoring committee is not needed. Any adverse effect related to the exercise intervention or any unintended effect will be registered.
Ethics and dissemination
National and international research ethics guidelines will be followed, including the Deontological Code of Ethics, Declaration of Helsinki, and current confidentiality laws concerning personal datain Spain (Ley Orgánica 3/2018, 5 December) and the European Union (European Parliament and Council Regulation EU 2016/619). Detailed, understandable oral and written information will be provided to patients and family members, and informed consent to participate will be signed by all participants. In patients with dementia, written informed consent will be obtained from the main caregiver (Additional file 1). The Redyor study protocol and the informed consent process have been reviewed and approved by the Clinical Ethics Committee of the Institut Hospital del Mar d´Investigacions Mèdiques, Barcelona, Spain (Comité Ètic d’Investigació Clínica Parc de Salut Mar: reference number 2015/6288/I) (Additional file 2). Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines will be followed throughout (32) (Additional file 3). This trial is supported by the Asociación Española contra el Cáncer (AECC) and was registered at www.clinicaltrials.gov with code NCT0209009911 on February 9, 2016. Amendments to the original submitted protocol are subject to further ethics review, and will be communicated to investigators and participants upon approval. Investigators and sponsor will communicate trial results to participants and healthcare professionals. Manuscripts will be prepared for submission to medical journals related to this field in order to contribute to HNC knowledge.